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Abstract
Introduction: Propofol infusion syndrome (PRIS) is a rare, but potentially lethal adverse effect of a commonly used
drug. We aimed to review and correlate experimental and clinical data about this syndrome.
Methods: We searched for all case reports published between 1990 and 2014 and for all experimental studies on
PRIS pathophysiology. We analysed the relationship between signs of PRIS and the rate and duration of propofol
infusion causing PRIS. By multivariate logistic regression we looked at the risk factors for mortality.
Results: Knowledge about PRIS keeps evolving. Compared to earlier case reports in the literature, recently
published cases describe older patients developing PRIS at lower doses of propofol, in whom arrhythmia,
hypertriglyceridaemia and fever are less frequently seen, with survival more likely. We found that propofol infusion
rate and duration, the presence of traumatic brain injury and fever are factors independently associated with
mortality in reported cases of PRIS (area under receiver operator curve = 0.85). Similar patterns of exposure to
propofol (in terms of time and concentration) are reported in clinical cases and experimental models of PRIS.
Cardiac failure and metabolic acidosis occur early in a dose-dependent manner, while arrhythmia, other
electrocardiographic changes and rhabdomyolysis appear more frequently after prolonged propofol infusions,
irrespective of dose.
Conclusion: PRIS can develop with propofol infusion <4 mg/kg per hour and its diagnosis may be challenging as
some of its typical features (hypertriglyceridaemia, fever, hepatomegaly, heart failure) are often (>95 %) missing and
others (arrhythmia, electrocardiographic changes) occur late.
Introduction
After its launch in 1986, propofol became one of the
most popular drugs used for induction and maintenance
of anaesthesia and for sedation in intensive care units
(ICUs). It is estimated that 1 billion 20-ml equivalents is
sold worldwide every year and this amount continues to
increase [1]. Over the last decade the average price of a
20-ml equivalent has dropped from US$5 to less than
US$3 [2]. Increased affordability of propofol together
with its potential to reduce mortality [3] and the length-
of-stay [4] of the critically ill resulted in a steep rise in
the use of propofol for non-procedural sedation of
patients in ICUs.
Propofol infusion syndrome (PRIS) is a rare but poten-
tially lethal side effect of propofol. There is no widely ac-
cepted definition, but in most cases various combinations
of the following are described: unexplained metabolic
acidosis, rhabdomyolysis, hyperkalaemia, hepatomegaly,
renal failure, hyperlipidaemia, arrhythmia, Brugada-type
electrocardiograph (ECG; elevated ST-segment and coved
T-wave) and rapidly progressive cardiac failure. The first
cases were described in children in the early 1990s [5–11],
and cases in adults were reported soon after [12–15]. PRIS
did not gain significant attention until Cremer et al. pub-
lished a landmark paper in The Lancet [16] of seven cases
of PRIS in a neurosurgical ICU and they were the first to
highlight that the cumulative dose of propofol was the
main risk factor for its development. A few months later
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the US Food and Drug Administration (FDA) warned
against the use of propofol for prolonged sedation in
paediatric populations [17]. In 2006 the FDA updated the
labelling information and limited the maximum dose of
propofol recommended for sedation to 4 mg/kg per hour
[18]. At the same time European regulatory authorities
suggested that patients be monitored for metabolic acid-
osis, hyperkalaemia, rhabdomyolysis or an elevated creat-
ine kinase level, and/or signs of heart failure. If any of
these conditions developed, they recommended a dosage
reduction or discontinuation of propofol [19, 20]. Despite
increasing public awareness and regulatory measures in
place, PRIS continues to occur and kill. A European
database of suspected adverse drug reactions run by The
European Medicines Agency registered a total of 394 cases
of PRIS between December 2001 and March 2015, of
which 137 (35 %) were fatal [21].
In this paper we analysed data from 153 patients from
case reports and case series published between 1990 and
2014. We also reviewed experimental (animal and
ex vivo) studies on mechanisms of PRIS. The primary
aim of the study was to determine the relationship of
propofol exposure in patients identified with PRIS with
clinical and laboratory outcomes. We used multiple
regression analysis to analyse factors associated with
fatal outcome of PRIS. Secondary aims were to find a
link between the clinical presentations of PRIS with
proposed cellular mechanisms and to describe trends in
the reporting of PRIS over time.
Methods
In order to find all available publications on the topic,
we used a three-stage search technique and minimised
language limitations. Consent for the study was not
required, as the reports had been previously published.
Firstly, we performed a search on the PubMed database
using the keywords “propofol-infusion syndrome” which
yielded 275 articles. With help from a medical librarian
we obtained full texts of all original case reports or case
series of patients where the authors felt there was, or may
have been, PRIS. We did not exclude any language and
obtained articles in English, German, Spanish, Chinese,
Danish and Norwegian. We used Google Translate to
extract the data from articles in Scandinavian languages
and the English abstract only for one article in Chinese. In
the second stage, we searched references of these articles
for further articles fulfilling the eligibility criteria described
above but not identified during our original search.
Finally, we also included reports of unexpected meta-
bolic acidosis and arrhythmia in patients on propofol
published prior to the 1998 definition of PRIS [22].
This resulted in 94 manuscripts (see Additional file 1
for the full list of references) reporting on 153
patients with suspected PRIS.
In the full texts of these papers we specifically looked
at patients’ demographic characteristics (sex and age),
underlying disease (categorized as traumatic brain injury
(TBI), respiratory infection, status epilepticus, other
neurological cause or others), average propofol dose
(mg/kg per hour), duration of propofol administration
(hours), symptoms of PRIS classified as a binary variable
(1 = present, 0 = absent or not reported), unexplained
metabolic acidosis, arrhythmias, other ECG changes,
cardiac failure, acute respiratory distress syndrome,
hypotension, acute kidney injury (AKI; any report of
oligoanuria or increased creatinine), rhabdomyolysis (or
elevated creatine kinase or myoglobin), lipaemia (or
increased plasma triglycerides), liver damage and un-
explained fever. We consider a sign as being present if
the original case report authors described it as a sign of
PRIS—in most case reports this causation is suspected if
a sign occurred or worsened after propofol administra-
tion and disappeared or improved after cessation of pro-
pofol administration. We did not analyse concomitant
medication (vasopressors and steroids) as these data
were missing in >50 % of published cases. In each case,
the outcome was defined as “survived” (if the patient
was reported to recover from PRIS) or “died”, regardless
of the report authors’ opinion on the cause of death.
These values were extracted by one of the authors (AK)
and independently checked by another (FD). In order to
describe the change in case reports over time, we arbi-
trarily divided case reports into three groups (n = 27, 53
and 72, respectively) demarcated by the years of publica-
tion: 2001 (the year of banning prolonged propofol infu-
sion in children and the acceptance of the existence of
PRIS in adults) and 2006 (the year when the safety limit
of 4 mg/kg per hour was recommended).
Statistical analysis
In order to describe trends over time, we used simple
linear regression. Multiple logistic regression analysis of
risk factors for mortality was performed in three steps.
Firstly, we performed univariate analysis of each inde-
pendent factor that might influence mortality. Continu-
ous variables (age, average dose and duration) were
categorised into quintiles. Variables without an asso-
ciated influence on mortality at p < 0.1 were then ex-
cluded. For the remaining variables we performed
correlation analysis and, if a significant (p < 0.05) correl-
ation was found between the two variables, only the one
with stronger prediction in univariate analysis was en-
tered into the final model. Finally, we performed mul-
tiple logistical regression analysis to calculate the
influence of every single independent variable on mortal-
ity. The receiver operator curve area under the curve of
the final model was calculated. Values are reported as
odds ratios (95 % confidence intervals). All calculations
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were performed using Stata Software (version 13.1; Stata
Corp. Ltd., USA), and p values <0.05 were considered
significant. Detailed step-by-step results of logistic
regression analysis are available in Additional file 1.
Results
Change of features of PRIS over time
As demonstrated in Additional file 2: Figure S1, PRIS
continues to be reported in the literature in both adult
and paediatric populations without a clear trend to a re-
duction. Among 153 cases of PRIS published between
1986 and 2015, 78 (51 %) had a fatal outcome. Fatality
rates in reported cases decreased over time from 74 %
(20–27 %) before 2001, to 64 % (34–53 %) between 2001
and 2006, and to 32 % (23–72 %) in cases reported after
2006. In 138 cases (90 %) patients developed PRIS as a
complication of non-procedural sedation in ICUs and in
15 cases (10 %) as a complication of the use of propofol
during anaesthesia.
The duration of infusion leading to PRIS in re-
ported cases increased over time and the mean pro-
pofol infusion rate decreased, leading to an overall
decrease in the cumulative propofol dose leading to
PRIS (see Additional file 3). Mean age of patients in
reported cases increased over time, and this trend is
apparent even if paediatric cases are excluded from
the analysis (data not shown).
There was no change in the underlying disease of
patients with PRIS over time (data not shown), but the
incidence of some reported signs of PRIS did change
(see Additional file 4). Arrhythmia, other ECG changes,
hypertriglyceridaemia and fever are all reported with
decreasing frequency. Metabolic acidosis remained the
most common symptom of PRIS with a constant inci-
dence at around 77 % in reported cases. See Additional
file 1: Table S1 for detailed extracted data from all case
reports.
Factors influencing mortality in published cases of PRIS
Demographic characteristics, underlying disease, fre-
quency of symptoms and their influence on mortality in
univariate analysis are summarized in Table 1. In order
to make sure that only variables independent of each
other were entered into the logistical regression model,
we performed a correlation analysis. There were signifi-
cant correlations between arrhythmias and other ECG
changes (R = 0.87, p < 0.001) and as expected between
the cumulative dose and both the infusion duration
(R = 0.47, p < 0.001) and average infusion rate (R = 0.38,
p < 0.001). We thus eliminated arrhythmia and cumula-
tive dose from the analysis. Hepatomegaly and fatty liver
were also eliminated, as these findings are more likely
reported in cases which included autopsy findings (i.e.
those with fatal outcome). We also found negative
correlations between age >55 and both average dose
(R = –0.34, p < 0.001) and arrhythmia (R = –0.39, p <
0.001). Multivariate logistical regression performed on
128 cases with complete datasets identified higher
dose, longer duration of infusion, development of
fever and the presence of TBI as factors associated
with increased mortality of PRIS, whilst all other fac-
tors were eliminated from the model (see Additional
files 5 and 6). Detailed step-by-step results of regres-
sion analysis can be found in Additional file 1.
Influence of propofol infusion rate and duration on signs
of PRIS
Additional file 7: Figure S5 demonstrates that actual pro-
pofol infusion rate is a factor significantly influencing
the frequency of fever (which occurs in <5 % of patients
with an infusion rate <4 mg/kg per hour, but in >40 %
with an infusion rate above 8 mg/kg per hour) and there
is a trend to similar dose dependency for cardiac failure
(p = 0.060) and metabolic acidosis (p = 0.059), which
both occur more frequently with the dose above
4 mg/kg per hour (Additional file 7). The other signs
of PRIS occur in similar frequencies across the range
of propofol infusion rates. When looking at the influ-
ence of the duration of propofol infusion leading to
PRIS (Additional file 8), arrhythmia and other ECG
changes occur more frequently after 48 hours of infu-
sion. The incidence of rhabdomyolysis and hypertri-
glyceridaemia rise after 96 hours. On the contrary,
metabolic acidosis occurs more frequently in cases
reporting a shorter duration of propofol administra-
tion leading to the development of PRIS.
Discussion
Our analysis of 153 published cases of PRIS shows that
this syndrome, or at least its reflection in the medical
literature, has changed over the last 24 years. A typical
patient who died with PRIS in the early 1990s was a child
with respiratory infection who developed PRIS after
having received an excessive dose of propofol [5–7]. Now-
adays, PRIS is more likely to be seen in an adult or elderly
patient sedated by a usual dose of propofol in an ICU in
whom mild unexplained acidosis and elevation of creatine
kinase is noted, sometimes with worsening of AKI and
arrhythmia, but other features of PRIS are often missing
[23–27]. This may reflect a change of prescription habits,
with more ICU patients exposed to propofol, but a smaller
proportion of them exposed to dangerously high doses.
Our multivariate analysis shows that, after adjustment for
covariates, there are only a few independent predictors of
death. The most important of these seems to be the cu-
mulative dose of propofol, being represented by both
mean infusion rate and the duration of infusion. Out of all
the other features of PRIS, which seem to increase the
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probability of death in univariate analysis, only the pres-
ence of TBI and fever were significantly related to PRIS
mortality after adjustment for other covariates. Other vari-
ables, most notably patient age, the presence of
arrhythmia or other ECG changes, were eliminated from
the model.
By studying the dependency of the frequency of PRIS
signs on the rate and duration of propofol infusion we
observed the following associations:
1. Dose-related signs of PRIS occur more frequently
with higher infusion rates, irrespective of the




Odds ratio P 95 % CI
Demography
Elderly (age >55 years) 29 (19 %) 0.11 <0.001 0.04–0.34
Child (age <18 years) 56 (36 %) 1.4 0.318 0.72–2.7
Male sex 80 (60 %)a 0.85 0.646 0.42–1.7
Underlying disease
Respiratory infection 22 (14 %) 2.28 0.093 0.87–6.0
Traumatic brain injury 43 (28 %) 4.7 <0.001 2.1–10.5
Status epilepticus 30 (20 %) 0.67 0.331 0.3–1.5
Non-trauma neurological dg. (cerebral vascular malformation,
aneurysm, sinus thrombosis, brain tumor etc.)
15 (10 %) 0.60 0.36 0.2–1.8
Other 43 (28 %) 0.25 <0.001 0.12–0.54
Propofol dose and duration of infusion
Average dose (continuous variable) 128 (84 %)b 1.12 0.08 0.99–1.28
Average dose above 5 mg/kg per hour 76 (59 %) 4.20 <0.001 1.98–8.9
Duration (continuous variable) 150 (98 %)c 1.005 0.109 0.999–1.012
Duration <20 hours 30 (20 %) 1.00 N/A N/A
Duration 20–60 hours versus <20 hours 35 (23 %) 43.5 <0.001 9.9–191.4
Duration >60 hours versus <20 hours 85 (57 %) 10.6 <0.001 3.0–37.7
Cumulative dose (continuous variable) 128 (84 %)b 1.001 0.079 0.999–1.002
Cumulative dose above 360 mg/kg 76 (59 %) 2.74 0.007 1.33–5.68
Symptoms
Metabolic acidosis 117 (77 %) 2.48 0.024 1.13–5.45
Brugada-like or ischaemic ECG 102 (67 %) 3.29 0.001 1.61–6.73
Arrhythmia 101 (66 %) 4.6 <0.001 2.19–9.55
Rhabdomyolysis 85 (56 %) 1.44 0.27 0.76–2.73
Acute kidney injury 60 (39 %) 1.02 0.944 0.53–1.96
Hypotension 45 (30 %) 2.15 0.037 1.05–4.4
Hyperkalaemia 37 (24 %) 2.86 0.009 1.29–6.34
Hypertriglyceridaemia 37 (24 %) 1.79 0.132 0.84–3.83
Cardiac failure 35 (23 %) 1.17 0.4 0.55–2.49
Fever 29 (19 %) 8.25 <0.001 2.71–25.15
Abnormal liver function test 20 (13 %) 0.94 0.899 0.37–2.4
Discolouration of urine 16 (11 %) 2.27 0.148 0.75–6.87
Hepatomegaly or fatty liver 16 (11 %) 4.73 0.019 1.29–17.36
Pulmonary oedema 4 (3 %) N/A N/A N/A
aMissing sex in 19 (12 %) patients
bMissing value for propofol dose in 25 (16 %) patients
cMissing value for duration in 3 (2 %) patients
CI Confidence interval, ECG Electrocardiograph, N/A Not available
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duration of infusion. This includes cardiac failure,
metabolic acidosis, fever, and perhaps hypotension.
Of note, the first two tended to be more frequent in
cases caused by a shorter duration of propofol
infusion.
2. Signs of PRIS dependent on duration of infusion
occur more frequently with longer propofol
infusions irrespective of dose; arrhythmia and other
ECG changes belong to this category, occurring
more frequently in cases where a whole range of
propofol doses were administered for more than
48 hours.
3. Signs of PRIS dependent on cumulative dose rise in
frequency with both the dose and time of
administration. Rhabdomyolysis and
hypertriglyceridaemia represent this category and
occur most frequently with high doses of propofol
after 96 hours of administration.
4. “Idiosyncratic” signs of PRIS occur independently of
the rate and duration of infusion. AKI and
hepatomegaly belong to this category, even though
the latter shows a trend to association with the
cumulative dose.
These patterns may reflect the different pathophysio-
logical mechanisms proposed to cause PRIS.
Proposed pathophysiological mechanisms for PRIS
Mitochondrial toxicity of many anaesthetics used in the
1980s [28] and the structural similarity of propofol to
co-enzyme Q led to early formulation of the hypothesis
that PRIS is caused by uncoupling or inhibition of the
respiratory chain. A series of animal experiments ad-
dressed this. Branca et al. [29, 30] exposed isolated rat
liver mitochondria to 0–100 μmol/l propofol (plasma
concentration in patients sedated with propofol is in the
range 5–30 μmol/l). They found a linear dose-dependent
reduction of respiratory chain capacity (measured as
maximal uncoupled respiration) and transmembranous
potential (ΔΨ), but no impairment of ATP synthesis up
to 75 μmol/l propofol. It should be stressed that in these
experiments succinate was used as a mitochondrial sub-
strate, feeding electrons to Complex II and bypassing
Complex I, which is often damaged during mitochondria
isolation. Rigoulet et al. [31] later demonstrated that
Complex I in isolated rat liver mitochondria is more sensi-
tive to inhibition by propofol than complex II and also
demonstrated the ability of propofol (25–400 μmol/l) to
cause a leak of protons through the inner mitochondrial
membrane, probably via dysfunctional ATP synthase.
Mitochondria isolated from rat hearts in similarly
designed experiments seemed to be more resistant to
propofol toxicity, as reduction of ΔΨ and inhibition of
ATP synthesis were only observed at >300 μmol/l
propofol [32]. In an ex-vivo study [33] on isolated
perfused guinea pig hearts, supratherapeutic propofol
concentrations (50–200 μmol/l) caused a delay in myoglo-
bin desaturation and cytochrome c reduction after expos-
ure to ischaemia, consistent with inhibition of the
respiratory chain, but not with uncoupling. Of note, these
effects were dependent on the dose of propofol, but not
on the duration of infusion (0–120 minutes). Decreased
activity of cytochrome c oxidase (complex IV) was inde-
pendently found in skeletal muscle biopsies of two pa-
tients with PRIS [34, 35]. The defect was not present in
skin fibroblasts suggesting an acquired rather than un-
detected inborn defect [35]. More recently, significantly
reduced activities but normal concentrations of all respira-
tory complexes were found in a patient who died of PRIS
[36], and complex IV was affected most.
New light has now been shed on the conflicting results
by a landmark study of Vanlander et al. [36] who in a
series of experiments combining a rat model of PRIS
and in-vitro exposure of tissue homogenates to propofol
demonstrated that propofol in therapeutic concentra-
tions interacts with co-enzyme Q and blocks electron
transfer from complexes I and II to complex III, whilst
much higher concentrations of propofol are needed to
block the activities of individual complexes. Out of these,
the activity of complex IV was the most sensitive to in-
hibition by propofol and only this complex could be
inhibited by the concentrations, which were achieved in
tissues of animals treated with propofol.
Another proposed mechanism of PRIS is inhibition of
fatty acid oxidation, formulated by Wolf et al. [37, 38]
and Withington et al. [39] who observed increased
plasma concentrations of acyl derivatives of carnitine in
children with PRIS, which normalised after cessation of
propofol infusion, suggesting a propofol-induced defect
of fatty acid oxidation [40]. Also, in one case, PRIS
seemed to be triggered by a ketogenic diet [41]. Critical
illness itself causes a switch from carbohydrate utilisa-
tion to oxidation of lipids. High levels of stress hor-
mones and insulin resistance activate endogenous
lipolysis and plasma free fatty acid levels increase [42].
The lipid vehiculum of propofol may further increase
the burden imposed on free fatty acid oxidation.
Duration of exposure to propofol seems to be a crucial
factor in the development of the defect of fatty acid
oxidation: in a patient on a propofol infusion (4.1–
6.6 mg/kg per hour) [38] plasma C4-carnitine species
rose steadily over the period of 5 days. The mechanism
by which propofol influences fatty acid oxidation is
unknown. One animal study [43] demonstrated an in-
hibition of the transport of fatty acid into mitochondria
at the level of carnitine-acyl transferase I. This enzyme is
activated by adenosine monophosphate-activated kinase
(AMPK). If propofol interferes with signalling function
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of co-enzyme Q [36], it may attenuate the activation of
fatty acid oxidation by AMPK [44], but the activity of
this enzyme has been increased in the myocardium of
propofol-sedated rabbits [45]. Finally, propofol triggered
apoptosis in human endothelial cell lines and increased
vascular permeability in mice [46], but the doses re-
quired to elicit these effect were orders of magnitude
higher than those seen in clinical situations.
In summary, current experimental data suggest that
propofol, structurally similar to co-enzyme Q, interferes
with electron flux from upstream complexes (I and II) to
complex III. In addition it interferes with fatty acid oxi-
dation, which builds up in plasma over time. Very high
doses of propofol seem to directly inhibit the activity of
complex IV and uncouple the respiratory chain by modi-
fying the structure of F1F0ATPase.
Our finding that mechanical cardiac failure and meta-
bolic (in most cases lactic [12, 34, 47–50]) acidosis occur
early (often within the first few hours [7, 23, 34, 51–53])
and in a dose-dependent manner, is consistent with a
direct inhibition of aerobic phosphorylation observed in
experimental studies. The heart is highly reliant on aer-
obic ATP synthesis [54] and acidosis may represent a
combination of hypoperfusion and cytopathic hypoxia in
tissues. Fever is reported more frequently with higher
propofol infusion rates and this may reflect mitochon-
drial uncoupling and energy dissipation as heat. Fever is
also an independent predictor of mortality in our model,
possibly identifying subgroups of patients who are more
susceptible to mitochondrial uncoupling. On the other
hand, arrhythmia and ECG changes occurred more fre-
quently in PRIS cases caused by prolonged propofol in-
fusions and were the only signs which were not seen in
animal models of PRIS triggered by short-term
(<38 hours) high-dose propofol [36, 43, 45, 55]. A pos-
sible explanation is that arrhythmia and ECG changes
are caused by elevated free fatty acids, which steadily in-
crease over days during propofol administration [37] and
are known to be proarrhythmogenic [56] (even more so
in combination with metabolic acidosis). Similarly,
rhabdomyolysis (a common feature of inborn defects of
fatty acid oxidation [57, 58]) is associated with the dur-
ation of propofol administration and may also be related
to the propofol-induced defect of fatty acid oxidation.
The frequency of hypertriglyceridaemia seems to also in-
crease with cumulative dose of propofol. If the dose of
lipid emulsions exceeds the capacity of hydrolysis in
plasma, triacylglyceroles accumulate in the blood and
are taken up by the reticulo-endothelial system, causing
hepatosplenomegaly, jaundice, and clotting disturbances
(“fat overload syndrome” [59]). Recommended lipid dose
for parenteral nutrition is 29–54 mg/kg per hour [60].
To match this dose, propofol as a 1 % solution in 10 %
intralipid has to run at 2.9–5.4 mg/kg per hour. Most of
the patients with PRIS exceeded this rate. Nonetheless,
it seems that excessive doses of lipid emulsions are gen-
erally well tolerated; rapid infusions of lipid emulsions
even in a range of 170–5000 mg/kg per hour have been
accidentally administered without side effects [61]. In
animal models of PRIS [45, 55], elevated triglycerides
was the only sign observed in control animals receiving
intralipid alone. In our study, even in the subgroup of
patients with infusions at a rapid rate administered over
an extended period of time, only a minority (40 %) de-
veloped hypertriglyceridaemia and this symptom had no
relation to the outcome of PRIS. Possible explanation is
that hypertriglyceridaemia represents an epiphenomenon
rather than a genuine part of PRIS. Other features of
lipid overload syndrome were absent in our series of pa-
tients with PRIS, with the exception of one patient with
hyperbilirubinaemia [9]. AKI is reported in 39 % of pa-
tients with PRIS. It was associated with rhabdomyolysis
in our series (R = 0.28, p = 0.0004) and myoglobin casts
were found in kidneys of rabbits treated with propofol
[55], but still there is no link to propofol dose or dur-
ation of infusion. It is likely that propofol may have been
only a minor factor among many others causing AKI in
sick ICU patients.
From the clinical perspective it is important to note
that exceeding recommended doses of propofol is not
only the main risk factor for the development of PRIS
[16, 20], but also that the probability that PRIS will be
deadly also increases—at least among the published
cases of PRIS. On the other hand, our analysis shows
that PRIS can develop with doses well within the recom-
mended safety limits and even after a relatively short
duration of administration. In these situations some typ-
ical features are often missing, which can make the diag-
nosis challenging. For example, with doses <4 mg/kg per
hour the frequencies of hypertriglyceridaemia, fever,
hepatomegaly and heart failure are <5 % in published
cases of PRIS, while after short infusions of higher doses,
ECG changes and arrhythmia may not be present and
PRIS can be manifested as unexplained cardiac failure
and metabolic acidosis. Propofol should automatically be
suspected if any of the signs of PRIS appear without
alternative explanation in an ICU patient on propofol
infusion. There is no specific treatment for PRIS and
the only way to prevent further deterioration and
death is to recognize PRIS early and stop the infu-
sion. Supplementation of co-enzyme Q may become a
promising therapeutic strategy (a propofol “antidote”)
in the near future [36].
The main limitation of our study is the risk of publica-
tion bias, i.e. that the published cases are not representa-
tive of the population of patients with PRIS. For
example, in our mortality analysis, alternative explana-
tions to a seemingly obvious causative relation between
Krajčová et al. Critical Care  (2015) 19:398 Page 6 of 9
PRIS mortality and propofol cumulative dose is that
non-fatal cases of PRIS may be more likely to be written
up and published if caused by only a small dose of pro-
pofol. Analogously, after safety limits of dosage were in-
troduced, authors may become less likely to report cases
of PRIS caused by propofol doses which had exceeded
these limits. Apart from the fact that not all cases of
PRIS are recognised and published, there is no guarantee
that all published cases analysed by us were reporting a
condition causally related to propofol administration.
PRIS is difficult to identify and to characterise in the
critically ill patient because of the overlap of the syn-
drome with common ICU clinical conditions and our
analysis is reliant on interpretation of clinical signs by
the authors of original case reports. It is possible that
the occurrence of a sign after the start of propofol infu-
sion was just coincidental manifestation of another con-
dition rather than a genuine manifestation of PRIS.
Similarly, death reported to be due to PRIS might have
occurred anyway, without a causal relation to propofol
infusion. In light of this, our mortality analysis must be
interpreted with caution. Unfortunately, obtaining pro-
spectively collected data in this relatively rarely occur-
ring syndrome would be extremely difficult. Adverse
drug reaction databases may be an alternative source of
information, potentially affected less by publication bias,
but the main problem will be the large proportion of pa-
tients with missing data. The European Medicines
Agency only provides cumulative data with basic demo-
graphic data and outcome [21], but further details of in-
dividual cases are not accessible. Fong et al. [62] looked
up PRIS symptoms in the FDA MedWatch [63] database
and aimed to determine predictors of death. Unfortu-
nately, the outcome was reported for less than one-third
of patients and among them the propofol infusion rate
and duration were reported in only 18 % of cases, for-
cing the authors to remove these key variables from
their mortality analysis. After doing so they found car-
diac symptoms, rhabdomyolysis, hypotension, metabolic
acidosis, renal failure, and age to affect survival in popu-
lations with at least one sign of PRIS. Even though most
of these signs were associated with mortality in univari-
ate analysis in our series, they were not significant in the
multivariate model.
Conclusions
In conclusion, after propofol labelling information up-
dates in 2001 and 2006, PRIS case reports continue to
occur with unchanged frequency, but its presentation
has evolved. More survivable cases, occurring with lower
infusion rates, have replaced lethal PRIS with multiple
clinical manifestations. In multivariate logistical analysis,
the rate and duration of propofol infusion, the presence
of TBI and fever were associated with higher mortality
in published cases of PRIS. Most experimental data
point towards mitochondrial toxicity of propofol. We
hypothesise that short-term administration of high doses
of propofol may cause metabolic acidosis and heart fail-
ure by inhibiting aerobic phosphorylation and fever by
mitochondrial uncoupling. With prolonged infusions,
fatty acid oxidation is likely inhibited by propofol or its
metabolite, which causes arrhythmia and other ECG
changes. Rhabdomyolysis occurs if the administered
dose is high enough, and in some cases this may exacer-
bate AKI. Hypertriglyceridaemia in the context of PRIS
may be an epiphenomenon caused by fat overload.
Key messages
 Propofol infusion syndrome (PRIS) may occur even
after short duration of infusion and with moderate
doses (<4 mg/kg per hour). In this situation,
diagnosis may be challenging as most typical
symptoms are missing.
 Overall mortality in reported cases of PRIS is 51 %
and is decreasing over time.
 Propofol infusion rate and duration, the presence of
TBI and fever are factors independently associated
with mortality in reported cases of PRIS.
 Metabolic acidosis and heart failure occur early and
in a dose-dependent manner, whilst rhabdomyolysis,
arrhythmia and other ECG changes are rather
dependent on the duration of propofol infusion.
 Experimental data suggest that early, dose-
dependent signs may be caused by inhibition of re-
spiratory chain, whilst late, time-dependent signs by
inhibition of fatty acid oxidation.
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